**JBI Critical Appiraisal Checklist**

1. **Artikel 1 (Wiviott *et al*., 2019)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

1. **Artikel 2 (Neal *et al*., 2017)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

1. **Artikel 3 (Tikkanen *et al*., 2015)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | ✔ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | ✔ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | ✔ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | □ | ✔ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

1. **Artikel 4 (Virstyuk *et al*., 2018)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | □ | □ | ✔ | □ |
| 1. Was allocation to treatment groups concealed?
 | □ | □ | ✔ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | □ | □ | ✔ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | □ | □ | ✔ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | □ | □ | ✔ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | □ | □ | ✔ | □ |

1. **Artikel 5 (Weber *et al.*, 2016)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

1. **Artikel 6 (Weber *et al.,* 2016)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

1. **Artikel 7 (Townsend *et al.*, 2016)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Ya | Tidak | Tidak Jelas | Tidak dapat diterapkan |
| 1. Was true randomization used for assignment of participants to treatment groups?
 | ✔ | □ | □ | □ |
| 1. Was allocation to treatment groups concealed?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups similar at the baseline?
 | ✔ | □ | □ | □ |
| 1. Were participants blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were those delivering treatment blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were outcomes assessors blind to treatment assignment?
 | ✔ | □ | □ | □ |
| 1. Were treatment groups treated identically other than the intervention of interest?
 | ✔ | □ | □ | □ |
| 1. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?
 | ✔ | □ | □ | □ |
| 1. Were participants analyzed in the groups to which they were randomized?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in the same way for treatment groups?
 | ✔ | □ | □ | □ |
| 1. Were outcomes measured in a reliable way?
 | ✔ | □ | □ | □ |
| 1. Was appropriate statistical analysis used?
 | ✔ | □ | □ | □ |
| 1. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
 | ✔ | □ | □ | □ |

**Pencarian Kata Kunci pada *Database***

|  |  |  |
| --- | --- | --- |
| Basis Data | Kata Kunci | Hasil Temuan |
| PubMed | (("SGLT-2 Inhibitor"[All Fields] AND "Blood Pressure"[All Fields]) OR "Albuminuria"[All Fields]) AND "Diabetes Mellitus Type 2"[All Fields] AND "Hypertension"[All Fields] | 1477 |
| Google Scholar | (((("SGLT-2 Inhibitor") AND ("Blood Pressure")) OR ("Albuminuria")) AND ("Diabetes Mellitus Type 2")) AND ("Hypertension") | 238 |
| Science Direct | (((("SGLT-2 Inhibitor") AND ("Blood Pressure")) OR ("Albuminuria")) AND ("Diabetes Mellitus Type 2")) AND ("Hypertension") | 138 |
| EBSCOhost | (((("SGLT-2 Inhibitor") AND ("Blood Pressure")) OR ("Albuminuria")) AND ("Diabetes Mellitus Type 2")) AND ("Hypertension") | 1925 |

Bukti hasil pencarian setiap database juga dimuat dalam bentuk NBIB/BIB/bibtext, Berikut adalah link yang memuat data-data tersebut:

<https://drive.google.com/drive/u/0/folders/1EKXLE_79d5pRf-ws4owXRivfYN1qPdPp>